Entering the Era of Non-Basic P1 Site Groups: Discovery of Xarelto™ (Rivaroxaban)

Publisher： Bentham Science Publishers

E-ISSN： 1873-4294|10|3|257-269

ISSN： 1568-0266

Source： Current Topics in Medicinal Chemistry, Vol.10, Iss.3, 2010-02, pp. : 257-269

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Protease inhibitors - Part 3. Synthesis of non-basic thrombin inhibitors incorporating pyridinium-sulfanilylguanidine moieties at the P1 site

By Scozzafava A.   Briganti F.   Supuran C.T.  

European Journal of Medicinal Chemistry, Vol. 34, Iss. 11, 1999-11 ,pp. : 939-952

Elsevier

Access to resources Recommend Favorite

Recent progress in the drug discovery of non-peptidic BACE1 inhibitors

By Hamada Yoshio   Kiso Yoshiaki  

Expert Opinion on Drug Discovery, Vol. 4, Iss. 4, 2009-04 ,pp. : 391-416

Informa Healthcare

Access to resources Recommend Favorite

Recent Progress in the Discovery of Non-Sarcosine Based GlyT1 Inhibitors

By  

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 2, 2010-02 ,pp. : 170-186

Bentham Science Publishers

Access to resources Recommend Favorite

Rivaroxaban demonstrates non-inferiority, halves major bleeding risk

By  

Reactions Weekly, Vol. 1, Iss. 1395, 2012-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Photoaffinity Labeling in Drug Discovery and Developments: Chemical Gateway for Entering Proteomic Frontier

By  

Current Topics in Medicinal Chemistry, Vol. 2, Iss. 3, 2002-03 ,pp. : 271-288

Bentham Science Publishers

Access to resources Recommend Favorite